oh8dG在恶性肿瘤中的研究进展

目的]观察和评价培美曲塞联合顺铂治疗晚期复治乳腺癌的疗效及不良反应。方法]回顾性分析2008年1月-2011年1月经病理证实的晚期复治乳腺癌患者38例．接受培美曲塞联合顺铂化疗方案治疗。对其疗效进行评价。结果]全组38例均可评价疗效，患者有效率（CR＋PR）为39．5％，疾病控制率（CR＋PR＋SD）为73．7％；中位TrP为5个月，中位OS为12个月；主要不良反应为皮疹、黏膜炎、恶心呕吐和骨髓抑制。结论]培美曲塞联合顺铂治疗晚期复治乳腺癌有一定的疗效，且毒性反应轻，可耐受，可以作为晚期乳腺癌治疗的方案之一。

Research Progress in oh8dG for Cancer

Purpose] To evaluate the efficacy and side effects of pemetrexed combined with cisplatin in the treatment for re-treated advanced breast cancer.Methods] From Jan 2008 to Jan 2011,38 patients with re-treated advanced breast cancer pathologically proven who received combination of pemetrexed and cisplatin regimen.The efficacy and side effects were evaluated.Results] All of 38 patients were evaluable for response.The response rate(RR) and disease control rate(DCR) were 39.5% and 73.7% respectively.The median time to progress(TTP) was 5 months and the median overall survival(OS) was 12 months.The main side effects were skin rash,mucositis,gastrointestinal toxicity and myelosuppression.Conclusion] Pemetrexed combined with cisplatin in the treatment for re-treated advanced breast cancer is effective with mild toxicity.It deserves the clinical expansion and further exploration.